{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-002873","form_type":"8-K","ticker":"PMDI","cik":"0000806517","company_name":"PSYCHEMEDICS CORP","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.024716+00:00","generated_at":"2026-06-02T01:32:36.342187+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Psychemedics reports Q1 2024 revenue down 9% to $5.4M; net loss widens to $0.7M","bullets":["Revenue $5.4M vs $5.9M in Q1 2023, a 9% decline.","Net loss $0.7M ($0.12 per share) vs loss of $0.4M ($0.07) in prior year.","CEO cites revenue decrease but remains optimistic; focusing on client acquisition and new market applications."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-002873","json":"https://secwatch.observer/filing/0001171843-24-002873.json","markdown":"https://secwatch.observer/filing/0001171843-24-002873.md","text":"https://secwatch.observer/filing/0001171843-24-002873.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/806517/000117184324002873/0001171843-24-002873-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/806517/000117184324002873/f8k_051424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:32:36.342187+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"10c74eb118f012a99a9551bf01e821e0c3617cee","claim":"PSYCHEMEDICS CORP reported the first quarter ended March 31, 2024 results: revenue $5.4 million, net income $0.7 million, EPS $0.12 per share.","evidence_excerpt":"The Company’s revenue for the quarter ended March 31, 2024, was $5.4 million versus $5.9 million for the quarter ended March 31, 2023, a decrease of 9%. Net loss for the quarter was $0.7 million, or $0.12 per share, compared to a net loss of $0.4 million, or $.07 per share, for the comparable quarter last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/806517/000117184324002873/0001171843-24-002873-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$5.4 million"},{"label":"Net income","value":"$0.7 million"},{"label":"EPS","value":"$0.12 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}